More on ARWR
Data
Financials
Upcoming Events
News
|
|||||
|---|---|---|---|---|---|
| Prev. Close | $63.60 |
|
|||
| Open | $61.69 | ||||
| 52 Wk High | $8.22 | ||||
| 52 Wk Low | $3.07 | ||||
| Day High | $61.79 | ||||
| Day Low | $57.33 | ||||
| P/E | N/A | ||||
| EPS | $-1.30 | ||||
| Volume | 2,820,334 | ||||
- Form 144 ARROWHEAD PHARMACEUTICAL Filed by: Hamilton James C
- Arrowhead Pharmaceuticals to Participate in Upcoming March 2026 Events
- Why Late-Stage CNS, Oncology Assets Are Becoming the Hottest Targets in Biotech M&A
- Goldman Sachs Reiterates Neutral Rating on Arrowhead Pharma (ARWR)
- Arrowhead Pharma (ARWR) PT Lowered to $78 at Morgan Stanley
- Arrowhead Pharmaceuticals Inc. (ARWR) Tops Q1 EPS by 10c
- Form 10-Q ARROWHEAD PHARMACEUTICAL For: Dec 31
- Form 8-K ARROWHEAD PHARMACEUTICAL For: Feb 05
- Arrowhead Pharmaceuticals Reports Fiscal 2026 First Quarter Results
- Ciena Set to Join S&P 500; Arrowhead Pharmaceuticals to Join S&P MidCap 400; ADT and OneSpaWorld Holdings to Join S&P SmallCap 600
Entities mentioned with ARWR
- Twitter | View Related Stories »
- Earnings | View Related Stories »
- FDA | View Related Stories »
- Definitive Agreement | View Related Stories »
- Maynard Um | View Related Stories »
- Mark Zuckerberg | View Related Stories »
- ARK | View Related Stories »
- 13G | View Related Stories »
- Show More...
